Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

about

Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.Erythrodermic psoriasis after discontinuation of ixekizumab.Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.

P2860

Q45977850-EC07D853-D186-489C-84CB-7B6ECAFB295C Q49223769-3B3A2E61-01AE-4EFE-947A-CE51331BBE8D Q55101112-E619A082-91B7-4699-ABBD-729049F26419

P2860

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

Item

http://www.wikidata.org/entity/Q38990571

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

@en

type

Item

label

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

@en

prefLabel

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

@en

P1476

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

@en

P2093

Yahiya Y Syed

http://www.w3.org/2001/XMLSchema#string

P2860

Definition of treatment goals for moderate to severe psoriasis: a European consensus

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

Consensus guidelines for the management of plaque psoriasis.

Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

Biologic fatigue in psoriasis.

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.

Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.

P2888

s40257-017-0254-4

P304

147-158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40257-017-0254-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1074249971

http://www.w3.org/2001/XMLSchema#string

P698

28138946

http://www.w3.org/2001/XMLSchema#string

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

about

P2860

P2860

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698